利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.029 秒)

    Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
    1.
    发明申请
    Nonpeptide substituted spirobenzoazepines as vasopressin antagonists 有权

    公开(公告)号：US20070135409A1

    公开(公告)日：2007-06-14

    申请号：US11549678

    申请日：2006-10-16

    申请人： Robert Chen ,  Min Xiang

    发明人： Robert Chen ,  Min Xiang

    IPC分类号： A61K31/55

    CPC分类号： C07D223/16 ,  C07D223/14 ,  C07D223/32 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/14

    摘要： The invention is directed to nonpeptide substituted benzodiazepines of Formula I, wherein A, X, n, R1, R2, R3, R4, R5, a and b are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.

    Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
    2.
    发明申请
    Nonpeptide substituted spirobenzoazepines as vasopressin antagonists 有权
    非肽取代的螺苯并氮平作为血管加压素拮抗剂

    公开(公告)号：US20060111567A1

    公开(公告)日：2006-05-25

    申请号：US10440914

    申请日：2003-05-19

    申请人： Robert Chen ,  Min Xiang

    发明人： Robert Chen ,  Min Xiang

    IPC分类号： A61K31/55 ,  C07D487/10

    CPC分类号： C07D223/16 ,  C07D223/14 ,  C07D223/32 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/14

    摘要： The invention is directed to nonpeptide substituted benzodiazepines of Formula I, wherein A, X, n, R1, R2, R3, R4, R5, a and b are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.

    摘要翻译： 本发明涉及式I的非肽取代的苯并二氮杂，其中A，X，n，R 1，R 2，R 3，R a和b如本说明书所述，其可用作加压素受体拮抗剂，用于治疗与加压素受体活性相关的病症，例如涉及增加血管的那些 阻力和心功能不全。 包含式I化合物的药物组合物和治疗诸如高血压，充血性心力衰竭，心脏功能不全，冠状动脉血管痉挛，心脏缺血，肝硬化，肾血管痉挛，肾衰竭，脑水肿和缺血，中风，血栓形成或水 保留也被披露。

    Substrate conditioning for corona charge control
    4.
    发明授权
    Substrate conditioning for corona charge control 有权
    基底调理电晕充电控制

    公开(公告)号：US07724003B1

    公开(公告)日：2010-05-25

    申请号：US11938355

    申请日：2007-11-12

    申请人： NanChang Zhu ,  Jainou Shi ,  Min Xiang ,  ZiangHua Liu ,  Goujun Zhang ,  Xiafang Zhang ,  Shiyou Pei ,  Liang-Guo Wang ,  Joseph R. Laia, Jr.

    发明人： NanChang Zhu ,  Jainou Shi ,  Min Xiang ,  ZiangHua Liu ,  Goujun Zhang ,  Xiafang Zhang ,  Shiyou Pei ,  Liang-Guo Wang ,  Joseph R. Laia, Jr.

    IPC分类号： G01R31/26

    CPC分类号： H01L22/14

    摘要： A measurement system for taking a reading in a test zone on a surface of a substrate. A chamber forms an environment, a surface treatment station dispenses a stabilizing chemical in the test zone, a charge deposition station deposits a charge in the test zone, and a QV measurement station takes a QV based measurement in the test zone. Where the surface treatment station, the charge deposition station, and the QV measurement station all interact with the substrate within the chamber. In this manner, reliable QV measurements are taken on the substrate by controlling charge spreading with the stabilizing chemical. QV measurement stability is also improved by reducing the influence of the time trending on substrates with reactive dielectrics, such as on silicon oxynitride and high-k surfaces.

    摘要翻译： 用于在基板表面上的测试区域读取的测量系统。 室形成环境，表面处理站在测试区域中分配稳定化学品，电荷沉积站在测试区域中沉积电荷，QV测量站在测试区域进行基于QV的测量。 表面处理站，电荷沉积站和QV测量站都与室内的基板相互作用。 以这种方式，通过用稳定化学品控制电荷扩散，在衬底上进行可靠的QV测量。 通过减少时间趋势对具有反应性电介质的衬底（例如氮氧化硅和高k表面）的影响也可改善QV测量稳定性。

    SUBSTITUTED SPIROHETEROCYCLES
    5.
    发明申请
    SUBSTITUTED SPIROHETEROCYCLES 有权
    取代的螺旋体

    公开(公告)号：US20080076753A1

    公开(公告)日：2008-03-27

    申请号：US11857891

    申请日：2007-09-19

    申请人： Min Xiang ,  Mona Patel ,  Philip Rybczynski ,  Joseph Gunnet ,  Keith Demarest ,  Richard Look ,  Bruce Maryanoff ,  Michael Costanzo ,  Stephen Yabut

    发明人： Min Xiang ,  Mona Patel ,  Philip Rybczynski ,  Joseph Gunnet ,  Keith Demarest ,  Richard Look ,  Bruce Maryanoff ,  Michael Costanzo ,  Stephen Yabut

    IPC分类号： A61K31/55 ,  A61P25/00 ,  A61P9/00 ,  C07D471/10 ,  C07D487/10

    CPC分类号： C07D487/10

    摘要： The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal insufficiency, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

    摘要翻译： 本发明涉及式I的非肽取代的螺杂肼苯并氮平，其可用作加压素受体拮抗剂，用于治疗与加压素受体活性相关的病症，例如涉及增加的血管阻力和心脏功能不全（包括充血性心力衰竭，低钠血症和高血压）的那些。 包含式I化合物的药物组合物和治疗诸如高血压，充血性心力衰竭，心脏功能不全，冠状动脉血管痉挛，心脏缺血，肝硬化，低钠血症，肾血管痉挛，肾功能不全，肾衰竭，糖尿病性肾病，脑水肿， 还公开了脑缺血，中风，血栓形成或保水。

    Method and apparatus for determining dielectric layer properties
    7.
    发明授权
    Method and apparatus for determining dielectric layer properties 有权
    用于确定介电层性质的方法和装置

    公开(公告)号：US08004290B1

    公开(公告)日：2011-08-23

    申请号：US12061447

    申请日：2008-04-02

    申请人： Xiafang Zhang ,  Nanchang Zhu ,  Yiping Feng ,  Min Xiang ,  Jianou Shi

    发明人： Xiafang Zhang ,  Nanchang Zhu ,  Yiping Feng ,  Min Xiang ,  Jianou Shi

    IPC分类号： G01R27/26 ,  G01R31/26

    CPC分类号： G01R31/129 ,  H01L22/14 ,  H01L2924/0002 ,  H01L2924/00

    摘要： A method and apparatus for determining dielectric layer properties are disclosed. Dielectric layer properties such as dielectric thickness, dielectric leakage or other electrical information may be determined for a multilayer film stack on a semiconducting or conducting substrate. The film stack may comprise a first dielectric layer between the substrate and an intermediate layer of semiconducting or conducting material, and a second dielectric layer disposed such that the intermediate layer is between the first and second dielectric layers. The dielectric layer properties may be determined by a) depositing electrical charge at one or more localized regions on an exposed surface of the second dielectric layer; b) performing a measurement of an electrical quantity at the one or more localized regions; and c) determining a property of the second dielectric layer from the one or more measurements.

    摘要翻译： 公开了一种用于确定介电层性质的方法和装置。 绝缘层厚度，电介质泄漏或其他电信息等介质层性质可以针对半导体或导电基片上的多层膜堆叠来确定。 薄膜叠层可以包括在基底和半导体或导电材料的中间层之间的第一介电层，以及布置成中间层位于第一和第二介电层之间的第二介电层。 电介质层的性质可以通过以下步骤来确定：a）在第二介电层的暴露表面上的一个或多个局部区域沉积电荷; b）执行所述一个或多个局部区域处的电量的测量; 以及c）从所述一个或多个测量确定所述第二电介质层的特性。

    SUBSTITUTED SPIROHETEROCYCLES
    8.
    发明申请
    SUBSTITUTED SPIROHETEROCYCLES 有权
    取代的螺旋体

    公开(公告)号：US20080076754A1

    公开(公告)日：2008-03-27

    申请号：US11857954

    申请日：2007-09-19

    申请人： Min Xiang ,  Mona Patel ,  Philip Rybczynski ,  Joseph Gunnet ,  Keith Demarest ,  Richard Look ,  Bruce Maryanoff ,  Michael Costanzo ,  Stephen Yabut

    发明人： Min Xiang ,  Mona Patel ,  Philip Rybczynski ,  Joseph Gunnet ,  Keith Demarest ,  Richard Look ,  Bruce Maryanoff ,  Michael Costanzo ,  Stephen Yabut

    IPC分类号： A61K31/55 ,  A61P25/00 ,  A61P9/00 ,  C07D471/10 ,  C07D487/10

    CPC分类号： C07D487/10

    摘要： The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

    摘要翻译： 本发明涉及式I的非肽取代的螺杂肼苯并氮平，其可用作加压素受体拮抗剂，用于治疗与加压素受体活性相关的病症，例如涉及增加的血管阻力和心脏功能不全（包括充血性心力衰竭，低钠血症和高血压）的那些。 包含式I化合物的药物组合物和治疗诸如高血压，充血性心力衰竭，心脏功能不全，冠状动脉血管痉挛，心脏缺血，肝硬化，低钠血症，肾血管痉挛，肾衰竭，糖尿病性肾病，脑水肿，脑缺血， 中风，血栓形成或保水性也被公开。

    SUBSTITUTED SPIROBENZAZEPINES
    9.
    发明申请
    SUBSTITUTED SPIROBENZAZEPINES 有权
    取代的SPIROBENZAZEPINES

    公开(公告)号：US20070179128A1

    公开(公告)日：2007-08-02

    申请号：US11735149

    申请日：2007-04-13

    申请人： Mona Patel ,  Philip Rybczynski ,  Min Xiang

    发明人： Mona Patel ,  Philip Rybczynski ,  Min Xiang

    IPC分类号： A61K31/55 ,  C07D223/14

    CPC分类号： C07C205/57 ,  C07D223/32

    摘要： The invention is directed to nonpeptide substituted benzazepines of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension, among others disclosed. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

    摘要翻译： 本发明涉及式I的非肽取代的苯并氮杂，其可用作加压素受体拮抗剂，用于治疗与加压素受体活性相关的病症，例如涉及增加的血管阻力和心功能不全的那些，包括充血性心力衰竭，低钠血症和高血压等 披露 包含式I化合物的药物组合物和治疗诸如高血压，充血性心力衰竭，心脏功能不全，冠状动脉血管痉挛，心脏缺血，肝硬化，低钠血症，肾血管痉挛，肾衰竭，糖尿病性肾病，脑水肿，脑缺血， 中风，血栓形成或保水性也被公开。